The expansion of welfare provision observed in all industrialized countries after the Second World War has been characterized by an increased level of state responsibility for health care provision. This trend has been observed in countries with predominantly market economies as well as in countries with command economies. Since the 1940s, health care expenditure from public and private sources has increased markedly both in per capita terms and as a percentage of gross domestic product in all industrialized countries. However, the precise ways in which different countries raise funds for and organize their health care systems vary. As a result, descriptive comparisons between countries can make fascinating and sometimes confusing reading; analytic comparisons which try to explain the diversity of international solutions to common problems are rarer and more difficult to accomplish.
Much of the existing literature involves comparisons between countries of the Organization for Economic Co-operation and Development, particularly between countries such as the United States, the United Kingdom, Germany, France, Australia and Canada. Conclusions obtained from these specific cases are often directly applied to other countries, often disregarding important historic, economic, cultural and social differences. Furthermore, most of the literature consists of general comparisons of health care systems. Few analyses provide comparisons of how changes at a general structural level translate themselves into health care provision for specific problems which health care systems, mutatis mutandis, have in common.
As part of this series, authors from four very different countries -Brazil, China, the Netherlands and New Zealand -which are less commonly encountered in comparative analyses, were invited to contribute. The health care system of each country has been described simultaneously, using complementary 'top down' and 'bottom up' approaches. A general description of the system, including the demographic and societal context, written by an health policy analyst has been complemented by a view from an health care professional working within the system on the national response to the Human Immunodeficiency Virus (HIV) pandemic in terms of size of the problem, disease control, health promotion and health care provision.
Although the four case studies do not pretend to provide a rigorous explanation of the differences between these health care systems, their juxtaposition does provide useful insights into how different systems deal with common problems.
HIV infection, and its sequelae the Acquired Immunodeficiency Syndrome (AIDS), is an apt disease to select when comparing health care systems. The 1980s saw the beginning and recognition of the HIV pandemic. It scuppered the notion, commonly adhered to in industrialized countries during the 1960s and 1970s, that the threat of infectious diseases had been 'conquered' by increasingly sophisticated biomedical technology. The recognition of HIV infection as a global problem then evoked a world-wide approach to its containment. Like all communicable diseases, HIV does not respect national boundaries, especially in the era of mass global travel. Strategies to contain the transmission of HIV and to look after those affected with AIDS are increasingly influenced by international bodies and the international flow of scientific knowledge. Yet the scale and patterns of infection across populations and the precise country-by-country health care system response are crucially affected by the culture (including sexual mores), history, prosperity and level of development of the health care system in each country. For instance, although the role of condoms in reducing HIV transmission has been widely recognized and publicly promoted in many European countries, because of moral objections by vocal sections of the population in the United States, condom use cannot be publicly promoted and advertised in the various US media.
At the level of the health care system as a whole, the case studies display a picture of countries confronting many of the same problems, but through health systems marked by great administrative diversity. Although all four countries currently use a combination of 'out-ofpocket' payments, private health insurance, social insurance or earmarked taxes and general taxation (Table 1 ), the proportion of expenditure which each accounts for and the services they are applied to vary widely. All four systems involve a number of payers and many providers with varying responsibilities and relationships each of which are the product of the history of the particular country.
Despite their differences, all four countries are pursuing policies to prevent an unchecked and inefficient rise in health services expenditure. All have sought in the recent past to alter the economic incentive structures within their systems with the aim of securing greater resource consciousness and efficiency. Concepts borrowed from market economics are applied, with varying degrees of subtlety and appropriateness, to health care. For example, in China, the decision to privatize immunization and vaccination services and charge users directly for them may appear strange to outside observers, given the collective benefits generated by individuals becoming immunized against communicable diseases. This perhaps reflects the depth of the desire, among certain groups in China, to embrace free market ideas.
In countries with largely publicly owned and run hospitals, the aim of establishing an operating environment in which providers become more cost and quality conscious has led to formal separation of responsibility for financing health care from its provision (the purchaser-provider split) with a view to stimulating competition between providers. This tends to be accompanied by moves to give hospitals and other providers greater freedom to manage their own affairs, while at the same time subjecting them to stricter financial constraints such as moving away from systems of retrospective payment at cost to prospective payment at average or below-average cost. A separation between purchasers and providers has been adopted in New Zealand and the Netherlands, although in the Netherlands, unlike New Zealand, patients are offered a choice of insurance packages leading to potential for competition on both the demand and supply side of the health care market.
In both countries, as elsewhere, similar difficulties are being experienced. The commissioning process, which underpins the purchaser-provider split, is dependent on accurate and contemporary information on the use, cost and outcome of particular health service interventions, information which is currently unavailable in both countries, as reported by Ashton and Schut. Likewise, in generating and sustaining any semblance of supply-side competition, governments can be reluctant to allow competition to threaten existing hospitals and can intervene for political reasons. Providers themselves tend to prefer to form cartels and reach agreement on the distribution of local markets rather than face the uncertain world of competition. As a result, the role of health care planning is far from defunct even in systems pledged to using market-like solutions to problems of the distribution and efficiency of health care. In all countries, those financing or purchasing health care face a common problem of how to obtain sufficient clinical and professional knowledge to convince health care professionals and the public that they are capable of determining the broad content and balance of health care. This relates particularly to their ability to eliminate the less cost-effective procedures and control the pace of medical innovation in the face of medical opposition and claims to autonomy from the state.
The success of any health care system, and changes associated with it, should be assessed in terms of its effectiveness, efficiency, equity and acceptability of health care delivery. However, it is often difficult to obtain reliable measures on these dimensions. For instance, many of the HIV-related programmes, described by the papers in this series, cannot be evaluated using these indices. For instance, in Brazil, the financial impact of new combination anti-retroviral therapy is currently being evaluated without reliable baseline data on the cost of treating the various stages of HIV infection. Furthermore, health care reforms tend to be continuous and rarely reach a stable state, so that monitoring on a continuing basis is necessary, using either longitudinal or serial cross-sectional methods.
Likewise, trade-offs often need to be made between the main objectives pursued by health care systems. Thus an increased emphasis on patients' choice of treatment may increase the resources required for its delivery; an increased emphasis on the acceptability of service provision may likewise reduce its efficiency. On the other hand, an overemphasis on efficiency may reduce the extent to which a system can attain an effective or equitable outcome. Thus choices may need to be made between these objectives, choices which will be heavily influenced by the cultural and political context in which these decisions are made.
Although increased levels of spending do not automatically equate to an increasingly cost-effective use of resources, economic differences between countries, and particularly resources available for expenditure on health care, clearly affect how different health care systems are able to tackle practical policy issues. For instance, whereas combination anti-retroviral therapy, which is expected to raise the cost of care for HIV-infected individuals considerably, may not pose an enormous burden to the Dutch health care system (as Danner reports in this series), the use of such combination anti-retroviral therapy may not be subsidized in New Zealand, not only suggesting different levels of spending but also possibly different priorities. Again, in Brazil, anti-retroviral monotherapy is currently publicly subsidized through the public health system, the SUS, but whether this will be extended to include combination anti-retroviral therapy is currently being debated on grounds of cost. In China, even antiretroviral monotherapy is excluded from public subsidy and there are no immediate plans to change this.
This series provides further proof, if proof were needed, that the response of health services to common health challenges will always be intimately linked to the features peculiar to the country in question. Recognizing that each health care system is firmly embedded in its own society highlights the onus placed on health care professionals to ensure that, by using national and international comparisons, health care delivery is cost-effective, equitable and acceptable to individuals and populations within that society. 
